Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quantum Cyber NVFRA:4TO 39 EBITDA Margin % is -3,044.13% as of Dec. 2025. GuruFocus rates FRA:4TO with a GF Score™ of 39/100 and a GF Value™ of €3.56. The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Quantum Cyber NV ranks worse than 96.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Quantum Cyber NV's EBITDA for the
six
months ended in Dec. 2025 was €-6.48 Mil. Quantum Cyber NV's Revenue for the
six
months ended in Dec. 2025 was €0.21 Mil. Therefore, Quantum Cyber NV's EBITDA margin for the quarter that ended in Dec. 2025 was -3,044.13%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Quantum Cyber NV EBITDA Margin % Related Terms
Quantum Cyber NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Quantum Cyber NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4TO vs PRPO, BIOQ, IDXG: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Quantum Cyber NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quantum Cyber NV EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quantum Cyber NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Quantum Cyber NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quantum Cyber NV (FRA:4TO) has a EBITDA Margin % of -3,044.13% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Quantum Cyber NV and its competitors. According to the industry distribution chart, Quantum Cyber NV ranks #197 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 96.6%.
Is Quantum Cyber NV's EBITDA Margin % too high?
Quantum Cyber NV's current EBITDA Margin % is -3,044.13%. Based on the distribution chart, Quantum Cyber NV ranks #197 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Quantum Cyber NV has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Quantum Cyber NV's EBITDA Margin % compare to PRPO and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Quantum Cyber NV ranks #197 out of 204 companies for EBITDA Margin %. This places Quantum Cyber NV in the lower half of its industry. The industry median EBITDA Margin % is 5.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Quantum Cyber NV and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quantum Cyber NV's current EBITDA Margin % is -3,044.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum Cyber NV stock overvalued right now?
Quantum Cyber NV (FRA:4TO) has a current EBITDA Margin % of -3,044.13%. The stock's GF Value™ is €3.56, compared to a current price of €8.00 — trading 124.7% above its estimated fair value. The current EBITDA Margin % is -3,044.13%. Quantum Cyber NV's overall GF Score™ is 39/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Quantum Cyber NV (FRA:4TO), the current EBITDA Margin % is -3,044.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quantum Cyber NV (FRA:4TO) Overvalued in 2026?
Based on GuruFocus' analysis, Quantum Cyber NV stock appears to be overvalued.
The current stock price of €8.00 is trading 124.7% above its estimated GF Value™ of €3.56.
Key valuation signals for FRA:4TO:
EBITDA Margin %: -3,044.13%
GF Value™: €3.56 vs. price of €8.00 (124.7% above fair value)
No single metric tells the full story. See the FRA:4TO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity. It aims to secure critical infrastructure and data against these emerging threats.
39GF Score
Get the complete analysis for FRA:4TO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4TO has been successfully added to your 
